Summary
• Phio Pharmaceuticals Corp. (PHIO) shares fell 7.2% in after-hours trading, closing at $1.16.
• The company reported a third-quarter loss of $0.44 per share, slightly better than the expected $0.45 loss, and announced significant clinical trial advancements.
• An important presentation on INTASYL technology is scheduled for November 17, 2025, at the Advanced Therapies USA Congress in Philadelphia.
PHIO Pharmaceuticals Corp. (NASDAQ: PHIO) experienced a notable decline in after-hours trading, with shares priced at $1.16, a drop of 7.2% compared to the last close of $1.25. This move occurred without a clear catalyst, leading investors to assess the stock’s recent performance amidst ongoing developments.
Performance and Recent Financials
In its latest financial update, Phio reported results for the third quarter of 2025, revealing an actual loss of $0.44 per share against an estimate of a $0.45 loss. While this represented a minor surprise, the company highlighted significant advancements in its clinical trials. Notably, progression to the fifth cohort at the maximum dose of INTASYL PH-762 demonstrated positive pathology results, including a 100% tumor clearance in one patient and greater than 90% near-complete response in another.
Additionally, the firm is expected to extend its cash runway beyond the first half of 2027, as it anticipates net proceeds from warrant inducement financing of approximately $12.1 million.
Upcoming Presentation at Congress
On November 17, 2025, Phio announced an important upcoming podium presentation at the Advanced Therapies USA 2025 Congress, which will take place from November 18-19 in Philadelphia. This event will shine a spotlight on its proprietary INTASYL® gene silencing technology, pivotal in the company’s mission to eliminate cancer. Such engagements are critical for building interest and support within the biopharmaceutical community, particularly as clinical results mature.
Volume and Trading Insights
During this after-hours trading session, Phio witnessed a trading volume of approximately 143,750 shares. The average volume over the last 10 days stands at about 460,997, while the 3-month average is significantly higher at around 2,754,377. The high volatility observed recently was marked by a weekly performance decline of nearly 24%, underscoring the stock’s instability.
Technical Indicators and Market Sentiment
From a technical perspective, the stock is showing an RSI of 18.35, indicating it may be oversold in the short term. However, its 20-day and 50-day SMAs reflect substantial declines of over 30% and 43%, respectively. The yearly performance paints a grim picture with a loss of 51.4%, highlighting ongoing challenges for the company within the competitive biopharmaceutical landscape.
Moving forward, investors will be evaluating how Phio navigates these challenging conditions, especially in light of its upcoming presentation and potential strategic updates amidst fluctuating performance metrics.